AGWCA
LGND icon

Annis Gardner Whiting Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$799 Hold
4
– – ﹤0.01% 1172
2025
Q4 		$757 Hold
4
– – ﹤0.01% 1082
2025
Q3 		$709 Hold
4
– – ﹤0.01% 1039
2025
Q2 		$455 Buy
+4
New +$428 ﹤0.01% 1200

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's LGND Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 4 shares worth $799. The position accounts for ﹤0.01% of the portfolio, ranked #1172.

Annis Gardner Whiting Capital Advisors first reported a position in LGND in Q2 2025 and has held it in 4 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors held 4 shares of Ligand Pharmaceuticals worth $799 as of Q1 2026.
  • Annis Gardner Whiting Capital Advisors left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Annis Gardner Whiting Capital Advisors's portfolio in Q1 2026, its #1172 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.